Dr. Marc Hedrick is the President and CEO at Plus Therapeutics, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.
Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
Andrew Sims is Vice President and Chief Financial Officer at Plus Therapeutics, Inc. Mr. Sims arrived at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over 50 acquisitions ranging from $5 million to $4 billion in purchase price.
Mr. Sims is a native of the United Kingdom and is now a proud U.S. citizen. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. He is a graduate of Buckingham University in the United Kingdom.
Russ Havranek is the Executive Vice President of Commercial and Corporate Strategy. He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics.
Mr. Havranek has over 28 years of leadership experience developing and commercializing diagnostic and therapeutic products at global, publicly traded, biopharma and medical device companies. His prior roles in marketing, strategy, business development, general management, and R&D focused on the oncology, rare disease, cardiology, and orthopedic markets. These roles were held at Johnson & Johnson, Guidant (now Abbott), Genentech (now Roche), DJO Global (now Enovis), Volcano (now Philips), and CareFusion (now Becton Dickinson).
Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.
Daniel Ortega is Vice President of Development and Technical Operations at Plus Therapeutics, Inc. He is responsible for end-to-end drug development, GMP manufacturing, clinical supply chain management, and CMC oversight across the company’s radiotherapeutic portfolio.
Mr. Ortega brings nearly 20 years of pharmaceutical industry experience, including technical and leadership roles at Azaya Therapeutics, Mission Pharmacal, and Viatris (formerly DPT Laboratories). His expertise includes leading GMP manufacturing, regulatory-aligned CMC execution, and complex technology transfers across small molecule, nanomedicine, and radiopharmaceutical platforms, with a focus on clinical development and commercial readiness.
Mr. Ortega holds a Bachelor of Science from the University of Texas at San Antonio and an MBA from Texas A&M University–San Antonio.
Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutical, diagnostics, and medical device sectors. He has led the development of payer engagement strategies, health technology assessment (HTA) dossiers, and value frameworks supporting product launches and commercialization for leading healthcare organizations.
Dr. Goodman has advised leading global healthcare organizations, including Pfizer, Gilead Sciences, and Moderna, and has worked closely with government agencies such as the Centers for Medicare & Medicaid Services on value-based pricing and reimbursement frameworks. He has also served as a healthcare policy advisor to the White House on multiple health reform initiatives, contributing to the development of reimbursement and access frameworks at both the federal and state levels.
Dr. Goodman holds a Ph.D. and Master of Healthcare Administration from the Harvard T.H. Chan School of Public Health and a Bachelor of Arts in Medical Communications from North Texas State University.
Dr. Colby Suire serves as Vice President of Research & Development at CNSide Diagnostics and Plus Therapeutics, where he leads scientific strategy and execution to advance the CNSide™ platform and strengthen the Company’s translational and diagnostic capabilities. Colby is responsible for expanding CNSide’s assay portfolio across high-value oncology indications, including implementation of FISH and next-generation sequencing technologies, and driving analytical validation, and operational scale-up through automation in CLIA-regulated environments.
Dr. Suire brings more than 18 years of experience in translational science and drug development, with a proven track record of advancing programs from discovery through clinical development and enabling regulatory milestones. His expertise spans preclinical pharmacology, biomarker strategy, and assay development, with direct contributions to IND-enabling programs and clinical-stage assets across oncology, immunology, and cell and gene therapy.
Prior to joining Plus Therapeutics, Dr. Suire served as CEO and Head of Development at K2 Biolabs, where he scaled translational services and expanded revenue-generating capabilities, and held senior leadership roles at Talaris Therapeutics and Neurogene. He has consistently built high-performing teams, established strategic partnerships, and accelerated development timelines to enhance program value and capital efficiency.
Dr. Suire earned his Ph.D. in Biomedical Science from The University of Texas Health Science Center at Houston and holds a B.S. in Biological Sciences from Louisiana State University.
Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development.
Prior to joining Plus Therapeutics as the Chief Development Officer, from October 2021 through April 2026, Dr. Daniels served as the chief development officer of Kiora Pharmaceuticals (NASDAQ:KPRX). In addition, from 2018 through 2021, Dr. Daniels served as the executive director and co-founder of Bayon Therapeutics until it was acquired by Kiora Pharmaceuticals in October 2021 and as chief executive officer of OccuRx Pty Ltd., a clinical stage biotechnology company targeting microvascular disease for ocular indications, from July 2020 through October 2021. Dr. Daniels is also a co-founder and director of Okogen, Inc., a specialty biotechnology development stage ophthalmic company focused on a novel therapeutic for the treatment of viral infections of the eye, since May 2016. Since January 2014, Dr. Daniels has served on the clinical advisory board of Bimini, LLC and was chief medical officer of Bimini from January 2014 to October 2021. From April 2012 to November 2016, Dr. Daniels served as vice president – marketing & sales for Tensys Medical, Inc. (an HBM portfolio company). Dr. Daniels received his B.S. from the University of California Berkeley, his M.D. from the University of California, Los Angeles School of Medicine, and his MBA from the University of California, Los Angeles Anderson School of Management.
Mr. Bradley is currently President and General Manager, CNSide Diagnostics, LLC. Previously, Mr. Bradley led the Hematology Business Unit at Abbott Laboratories (NYSE: ABT) as General Manager. Before joining Abbott Labs, Mr. Bradley served as Senior Vice President of Corporate Development and Chief Marketing and Sales Officer of Luminex, Inc. (NASDAQ: LMNX – acquired by Diasorin for $1.8B in 2021). Previously, Mr. Bradley spent 17 years at Beckman Coulter, Inc. (acquired by Danaher (NYSE: DHR) for $6.8B), where he served in roles of increasing responsibility, including global commercial leadership of Beckman Coulter’s flow cytometry business and as the director of the Beckman Coulter CARES initiative, leading the company’s HIV clinical monitoring business in developing regions around the globe. During his tenure as a senior executive in the life science and clinical diagnostics markets, Mr. Bradley has completed the evaluation, market assessment, and successful commercial launch of multiple clinical diagnostics and life science technologies. Mr. Bradley obtained a B.Sc. Immunology and Biochemistry from Monash University, Melbourne, Australia.
